Find and Join

News Logo

• Tattoos, legal counsel, and good info

  If APC had a tattoo on its bicep — if we had a bicep, I mean — it might well read “Consult legal counsel.” read more →

• State advocacy update

  APC sent a letter to the New Mexico Board of Pharmacy this week commenting on its proposed amendments that would align the state with USP (good), but would also require that pharmacists ensure all flavors are inert (yikes). read more →

• Board approves new officer succession

  The APC Board of Directors has voted to name Gina Besteman (previously vice president) the board chair-elect after the resignation of Michelle Moser from the position. Besteman will assume the chair in January 2025. read more →

• FDA is concerned about compounded GLP-1 dosing errors

  Earlier this week APC received a letter from the FDA explaining the agency's concerns regarding dosing and patient usage of compounded semaglutide and tirzepatide. read more →

• Did you get your Compounding Pharmacy Snapshot?

  If you haven’t already, don’t forget to download and share the 2023-2024 edition of our Snapshot of Pharmacy Compounding in America. read more →

• After report, FTC to sue PBMs

  On Tuesday, the Federal Trade Commission released a scathing, two-years-in-the-making report about PBMs. read more →

More News

PCCA Ad

Blank

Medisca Ad

Blank

Fagron Ad

Blank

Wedgewood Ad

Blank

TopiClick Ad

EduCon is the conference for keeping your team members current and compliant, and it’s coming up February 9-10, 2023. Best of all, you can earn up to 12 CE hours.

With this in mind, here are two programs to further incentivize your EduCon registration: one on pharmacy law and another on patient safety:

• And Now a Word from Legal Counsel… Beta lactams? Semaglutide compounding? Insanitary conditions? Animal compounding? This session will address law and regulations pertaining to compounders, including the current state of the Federal Food, Drug and Cosmetic Act Section 503A on compounding shortage medications and substances such as peptides, DTE and bHRT therapies. Implementation of revised USP guidelines for sterile and non-sterile drug products, as well as the future of interstate distribution of compounded drug products, will be discussed.
• Ask the Testing Lab: Common Questions from Compounders: The new versions of USP <795> and <797> will become official on November 1, 2023. The presentation will provide details of several microbiological, biological, and analytical tests utilized in extending BUDs within the framework of the new <795> and <797>. Case studies will be provided to highlight the outcomes which can occur when the CSP/CNSP does not meet the expected outcomes.

For the complete list of speakers and presentations, and to register, please visit our EduCon web page.